Ulku Kandemir, Fikret Maltepe, Baran Ugurlu, Necati Gokmen, Asli Celik
Index: BMC. Anesthesiol. 13 , 28, (2013)
Full Text: HTML
Accidental intravenous exposure to bupivacaine is highly cardiotoxic and may lead to death. Positive inotropic agents are usually utilized in resuscitative efforts. We have compared the efficacy of levosimendan, a novel inotropic agent, with dobutamine and their combination in a rat model of bupivacaine intoxication.Twenty-eight male Wistar albino rats weighing between 250-300 g were divided into these four groups: control (C), levosimendan (L), dobutamine (D) and dobutamine+levosimendan (D+L). Bupivacaine was administered at a dose of 3 mg/kg/min until cardiac arrest occurred or for 120 min. ECG, heart rate, blood pressure, arterial blood gases, and end tidal CO2 levels were monitored. Levosimendan was administered as a bolus of 12 μg/kg for 10 min and continued as an infusion at 0.3 μg/kg/min. Dobutamine was infused at a dose of 3 μg/kg/min. The time required for a 50% and 75% decrease in heart rate and blood pressure with a total time to cardiac arrest and bupivacaine dose for obtaining cardiac arrest were analyzed.Time periods for heart rate reductions of 50% and 75% were significantly longer in groups L (903, 1198 s), D (984, 1542 s) and L+D (1705, 3152 s) compared with the control group (345, 538 s p < 0.001). Median times to mean blood pressure reductions of 50% and 75% were 399 - 504 s in the control group, 1005 -1204 s in group L, 685 - 1009 s in group D and 1544- 2982 s in group L+D, and the difference was significant compared with the control group. Median time duration to asystole was 703 s in the control group compared with 1385 s in group L, 1789 s in group D and 3557 s in group L+D. Time to cardiac arrest was significantly higher in all 3 study groups. It was also significantly higher in the L+D group compared with both groups L and D separately.A combination of dobutamine with levosimendan significantly increased survival times in this bupivacaine-induced toxicity rat model compared with the control, levosimendan, and dobutamine groups.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Levosimendan
CAS:141505-33-1 |
C14H12N6O |
Levosimendan exerts anti-inflammatory effects on cardiac myo...
2015-02-01 [Thromb. Haemost. 113(2) , 350-62, (2015)] |
Effect of levosimendan on the contractility of muscle fibers...
2015-01-01 [Skelet. Muscle 5 , 12, (2015)] |
A Bayesian network meta-analysis on the effect of inodilator...
2015-05-01 [Br. J. Anaesth. 114 , 746-56, (2015)] |
Influence of levosimendan postconditioning on apoptosis of r...
2015-01-01 [PLoS ONE 10(1) , e0114963, (2015)] |
The effects of levosimendan on brain metabolism during initi...
2012-01-01 [BMC Neurol. 12 , 81, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved